RxDoctor Payments Data

Pamela Matthews

Psychiatric/Mental Health, Adult · Bourne, MANPI 1558852301

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.5% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 29.8% of the total. Reporting peaked in 2021 at $1,408 and has fallen 82.3% since, to $249 in 2025. Among psychiatric/mental health, adult clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,912in general payments, 2019–2025

Across 162 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$868
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$334
  • Sunovion Pharmaceuticals Inc.$255
  • Otsuka America Pharmaceutical, Inc.$240
  • Lundbeck LLC$233
  • Alkermes, Inc.$224
  • plus $758 from 8 others

What the payments were for

  • Food & beverage$2,83897%
  • Education$743%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,912 in reported general payments places this provider in the 90th percentile of 92 psychiatric/mental health, adult providers in Massachusetts.

See all psychiatric/mental health, adult providers in Massachusetts

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine44$284,400
AustedoDeutetrabenazine14$70,279
VraylarCariprazine Hcl12$20,116
Perphenazine14$969
Venlafaxine Hcl ErVenlafaxine Hcl22$751
Bupropion XlBupropion Hcl12$327
Clonazepam25$146
Trazodone Hcl12$117
Lamotrigine12$76
Zolpidem Tartrate13$70
Diazepam11$41
Lorazepam15$35

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$203$354,67858 claims
AbbVieVraylar$868$20,11612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 92 psychiatric/mental health, adult providers in Massachusetts.

Other psychiatric/mental health, adult in Bourne

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →